摘要
目的评估慢性乙型肝炎合并非酒精性脂肪性肝病患者应用恩替卡韦联合水飞蓟宾葡甲胺治疗的效果。方法选择2018年1月至2020年1月本院感染科收治的80例慢性乙型肝炎合并非酒精性脂肪性肝病患者作为研究对象,根据随机数字表法分为对照组和观察组,各40例。对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合水飞蓟宾葡甲胺治疗,比较观察两组治疗效果。结果观察组治疗总有效率为95.00%,高于对照组的70.00%,差异具有统计学意义(P<0.05)。观察组HBsAg、AST、ALT和血清HBV DNA均低于对照组,差异具有统计学意义(P<0.05)。观察组PⅢNP、IV-C、LN、HA均小于对照组,差异具有统计学意义(P<0.05)。结论慢性乙型肝炎合并非酒精性脂肪性肝病患者应用恩替卡韦联合水飞蓟宾葡甲胺治疗效果显著,值得临床推广应用。
Objective To evaluate the efficacy of entecavir combined with silybin meglumine in the treatment of patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease.Methods 80 patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease who were admitted to the Department of Infectious Diseases of our hospital from January 2018 to January 2020 were selected as the research subjects,and they were divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The control group was given entecavir treatment,observation group was given entecavir combined silybin meglumine treatment.The therapeutic effects between the two groups were compared.Results The total effective rate in the observation group was 95.00%,witch was higher than that70.00% in the control group,and the difference was statistically significant(P<0.05).HBsAg,AST,ALT and serum HBV DNA in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).PⅢNP,IV-C,LN and HA in the observation group were significantly lower than those in the control group(P<0.05).Conclusion The effect of entecavir combined with silybin meglumine in the treatment of patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease is significant and worthy of clinical application.
作者
胡怀阳
黄耀辉
吴莉华
HU Huaiyang;HUANG Yaohui;WU Lihua(Department of Infection,Hui'an County Hospital,Fujian Province,Quanzhou,Fujian,362100,China)
出处
《当代医学》
2022年第8期44-46,共3页
Contemporary Medicine
